Accure Therapeutics is a R&D pharma company dedicated to developing innovative medicines to treat patients suffering from Central nervous system (CNS) diseases, a major medical challenge.
Total raised: $9.97M
Investors 2
| Date | Name | Website |
| - | Alta Life ... | altals.com... |
| 05.11.2025 | Asabys Par... | asabys.com... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.04.2025 | - | $1.6M | - |
| 27.05.2020 | Series A | $8.37M | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.04.2025 | The Dawn of a New Era in Neurology: Innovations Reshaping Diagnosis and Treatment | The world of neurology is undergoing a seismic shift. New technologies are like fresh paint on an old canvas, revealing vibrant possibilities for diagnosis and treatment. From advanced imaging techniques to groundbreaking gene therapies, th... |
| 07.04.2025 | Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg national research Fund | Barcelona neuroscience R&D company Accure Therapeutics has received two grants totalling €1.46 million for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibit... |
| 03.03.2022 | Oculis in-licenses neuroprotective drug candidate for glaucoma | |
| 02.03.2022 | Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics | Lausanne, Switzerland, and Barcelona, Spain, March 2, 2022 – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics,... |
| 02.03.2021 | Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01 | https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/ |
| 12.02.2021 | Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy | https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/ |
| 10.02.2021 | Accure Therapeutics – Webinars on Neuroprotection for Brain Diseases Program | https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/ |
| 26.01.2021 | Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer | https://accure.health/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/ |
| 12.01.2021 | Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists | Five neurology experts join CNS specialist’s scientific advisory board to support clinical trial development of disease modifying drug candidates Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D eng... |
| 27.05.2020 | Accure Therapeutics launches with €7.6M Series A round | Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI) invest in new company that will develop portfolio of new medicines to address CNS diseases Barcelona, Spain, May 26, 2020 – Accure Therapeutics, a new ph... |
Show more